Novo Nordisk-BBDC New Investigator Award 2022-2024


This award is intended to support a new clinician-scientist or basic scientist in the early stage of their career. One Novo Nordisk-BBDC New Investigator Award will be made available for this competition.

Eligibility Requirements:

  • Faculty who have held an $80,000 BBDC-Sun Life Financial New Investigator Award previously are not eligible to apply.
  • Faculty are eligible for this funding normally within five years of their first faculty appointment at any university or hospital research institute appointment as a Scientist, whichever occurred first. (The applicant must have received their first faculty appointment or hospital research institute appointment as Scientist on July 1, 2017 or later). Those who have experienced a career interruption must provide an explanation with their application. 
  • The applicant must be a basic scientist or a clinician-scientist (by official job description and with minimum 75% time protected for research) who holds or will hold a faculty appointment with the University of Toronto at the level of assistant, associate or full professor. Applicants who have not yet taken up their faculty appointment at the University of Toronto must do so by July 1, 2022.
  • The applicant must be conducting diabetes-related research at the University of Toronto or an affiliated institution at the time of award commencement.
  • The applicant should be a registered member* of the Banting & Best Diabetes Centre, although membership is not required for those who do not currently hold a U of T faculty appointment but expect to by July 1, 2022. (*Faculty who are new to the field of diabetes research and are not members of the BBDC can request free membership by contacting the Centre prior to submitting an application.  For more information about BBDC membership, please view the Membership section of this website).

Questions regarding eligibility should be directed to the Banting & Best Diabetes Centre before submitting an application.

Relevance to Diabetes:

This funding program supports original research on the physiology and pathophysiology of diabetes that would be published in a diabetes-focused journal. Research proposals can include any aspect of laboratory, animal, or human research. Areas of research which are considered relevant to diabetes include the pathogenesis of diabetes and its complications, normal and pathological pancreatic islet function and intermediary metabolism, pharmacological mechanisms of drug and hormone action, and biochemical and molecular aspects of normal and abnormal biological processes.


One award of $90,000 is available.

Duration of Support:

Two year funding period begins July 1, 2022 and ends June 30, 2024.

Use of Funds:

  • Funds may be used for diabetes research support (examples: supplies; materials; services; salary support for research staff, technicians, and trainees such as graduate or summer students and postdoctoral fellows).
  • Funds may be used for trainee and investigator travel to conferences or attendance of virtual conferences.
  • Up to $10,000 may be used for the purchase of equipment.
  • Requests from clinician-scientists for full or partial use of funds for personal salary support will be considered, but must be accompanied by a detailed letter explaining how, as a result of this award, the applicant’s clinical activities will be reduced to allow more time to be devoted to diabetes research. The letter must be signed by the Department Chair and Division Director and must clearly commit that the support will be used to reduce clinical activities.
  • Requests from basic science faculty for personal salary support will not be considered.
  • Use of funds for multiple purposes is acceptable.
  • Use of the funds must be fully justified.
  • Use of funds for institutional overhead fees is not permitted.

Judgment Criteria:

Applications will be evaluated on the following criteria:

  • The applicant (contributions to the field; research accomplished to date; future potential)
  • The research proposal. Innovative, original research will be highly ranked.
  • Relevance to diabetes
  • The proposed use of funds and ability to justify proposed use of funds.
  • A minor component of the evaluation will be based on other factors that the reviewers consider relevant to this competition.

Application Procedure:

Submit a completed application form to the Banting & Best Diabetes Centre by the application deadline date.

Download the 2022-2024 Novo Nordisk-BBDC New Investigator Award application form (PDF)

Application Deadline:

Applications must be received by 4 p.m., October 26, 2021.  Late or incomplete applications will not be considered.


All applicants will be notified in February 2022. Funding decisions will also be posted on our website.

Other Terms:

Ethics Approvals and Certifications: If this research involves human subjects, animals, biohazards or stem cells the principal applicant will be required to obtain approvals from their institution by the time of funding commencement on July 1. Approvals are not required to be submitted with this application; however, funds will not be released to successful applicants until all approvals have been obtained and forwarded to the BBDC.

Acknowledgement: Support from the “Novo Nordisk-BBDC New Investigator Award” must be acknowledged in all publications, presentations and communications that arise from this funding. Failure to acknowledge this support will result in future ineligibility for BBDC funding programs.

Reporting Requirements:

The successful applicant is required to provide the BBDC with a detailed written report and financial statement within three (3) months of the end of the funding period.

Written Report must include the following:

  • A description of how the money was spent.
  • A description of the research project and results to date.
  • Whether or not any publications were generated as a result of this funding.
  • If so, was the BBDC’s support acknowledged in the publications?
  • If applicable, a copy of all relevant manuscripts published and submitted must be attached to the report.

Financial Statement:  A detailed financial statement must be forwarded to the BBDC directly from the institution’s finance department itemizing all expenses and showing the final balance. All unspent funds must be returned to the Banting & Best Diabetes Centre within three months of the end of the funding period.

Failure to provide either the written report or financial statement will result in future ineligibility for BBDC funding programs.


Rose LaBarbera
Phone: (416) 978-4656